| Active substance | pembrolizumab |
| Holder | MSD Belgium BV/SRL |
| Status | Closed |
| Indication | in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1 |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 09/08/2022 |